Originally Aired: May 10, 2023
Time: 11:00 am–3:00 pm ET
A quarter of a century has passed since the development of pioneering gene-targeted anti-cancer drugs like Herceptin and Gleevec. Since then, we have witnessed many more drug approvals in precision medicines, spanning a wide range of therapeutic indications. In addition, the irrefutable power of precision medicine has been demonstrated with the many stories of patients returning from hospice or overcoming a terminal diagnosis to resume healthy lives.
With the precision medicine market projected to exceed $175 billion by 2030, the future of healthcare is stacked with opportunities to treat patients more precisely than ever. Yet we still face limitations in our understanding of human biology and associated treatments. Success stories are still too few, not least within the rare disease community. Debate continues amongst a group of passionate stakeholders who are trying to implement the requisite frameworks for future success.
Building off the success of the State of Biotech and State of Genomics & NGS virtual events (hosted by our sister magazine GEN), our inaugural State of Precision Medicine brought together leading physicians, scientists, executives, and patient advocates across the broad diagnostic, therapeutic, regulatory, data and advocacy landscape. Together, we highlighted how far we’ve come and how we can build, scale and industrialize new systems, all for democratizing precision medicine for the benefit of patients around the globe.
Guest Speakers Include
Produced with support from:
